IGFBP1hiWNT3Alo Subtype in Esophageal Cancer Predicts Response and Prolonged Survival with PD-(L)1 Inhibitor

Meichen Liu(Chengdu University of Traditional Chinese Medicine), Ke‐Neng Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Liang Dai(Shanghai University of Traditional Chinese Medicine), Hongsong Chen(Inner Mongolia University for Nationalities), Wanpu Yan(Peking University), Jiancheng Luo, Dongbo Chen(Diponegoro University)
Biology
October 27, 2022
10.3390/biology11111575
Cited by 3

Related Papers

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
|JAMA|2024|359
Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma
|Journal of Experimental & Clinical Cancer Research|2015|271
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2024|233
Mouse Embryonic Head as a Site for Hematopoietic Stem Cell Development
|Cell stem cell|2012|192